Press Release
Details
AVROBIO to Share Clinical and Pipeline Updates at Virtual R&D Day
AVROBIO to Share Clinical and Pipeline Updates at Virtual R&D Day
Event to be webcast on
The Virtual R&D Day also will include an in-depth review of the company’s continued optimization of plato®, AVROBIO’s proprietary platform designed to bring gene therapies to patients worldwide. Innovations to be discussed include the company’s pioneering approach to personalized conditioning with precision dosing.
In addition, the company will discuss its path to market strategy and next wave of lentiviral gene therapy programs, including the recently announced program in Hunter syndrome.
In addition to members of AVROBIO’s management and scientific teams, R&D Day speakers will include a world-leading stem cell transplant clinician as well as a globally renowned cell and gene therapy CMC and product development expert.
A live webcast of the Virtual R&D Day and accompanying slides will be available under “Events and Presentations” in the Investors section of the company’s website at www.avrobio.com. An archived webcast recording of the event will be available on the website for approximately 30 days. If you are a member of the investment community and would like to attend, please RSVP to lauren.shaughnessy@westwicke.com.
About
Our vision is to bring personalized gene therapy to the world. We aim to halt, reverse or prevent disease throughout the body with a single dose of gene therapy designed to drive durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and we also are advancing preclinical programs in Hunter syndrome and Pompe disease.
Forward-Looking Statement
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our prospective product candidates, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, anticipated benefits of our gene therapy platform including potential impact on our commercialization activities, timing and likelihood of success, and the expected benefits and results of our implementation of the plato platform in our clinical trials and gene therapy programs, including the use of a personalized and ultra-precision busulfan conditioning regimen. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.
Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005252/en/
Investor Contact:
Westwicke, an
339-970-2843
chris.brinzey@westwicke.com
Media Contact:
Ten
617-581-9333
stephanie@tenbridgecommunications.com
Source: